Trial results

Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial

NCT07030621 on ClinicalTrials.gov · last registry update 2025-06-22

Registered but not yet open, with 436 participants planned. Due to report 31 July 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: mRS at 90-days. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for cardiovascular disease, so this is asking a further question rather than establishing the drug works at all.

Status

NOT_YET_RECRUITING

Phase

P3

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

RenJi Hospital

Sponsor type

Other

Enrollment

436

Started

2025-07-01

Primary completion

2027-07-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

mRS at 90-days

Conditions studied

Acute Ischemic Stroke

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.